EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Impact of Impaired Renal Function on the Efficacy and Safety of Second‐Line Tyrosine Kinase Inhibitor Therapy After First‐Line Immuno‐Oncology Combination Therapy in Metastatic Renal Cell Carcinoma: A Japanese Multicenter Retrospective Study

Naoki Fujita iD, Yuto Matsushita iD, Takahiro Kojima, Yukari Bando iD, Takahiro Osawa iD, Tomokazu Sazuka iD, Keisuke Goto iD, Kazuyuki Numakura, Kazutoshi Yamana, Shuya Kandori iD, Yoshihide Kawasaki iD, Takuma Kato iD und 9 weitere

International Journal of Urology · 2025

DOI: 10.1111/iju.70172 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Urology, 2025. Verfasst von Naoki Fujita und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Protein Kinase Inhibitors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the effects of renal impairment at the time of second‐line tyrosine kinase inhibitor (TKI) therapy initiation and rapid renal function decline during first‐line immuno‐oncology (IO) combination therapy on metastatic renal cell carcinoma (mRCC) patients treated with second‐line TKIs.

Methods

This multicenter retrospective study included 243 mRCC patients treated with first‐line IO combination therapy, followed by second‐line TKI therapy. Patients were divided into three groups using the estimated glomerular filtration rate (eGFR; mL/min/1.73 m 2 ) at the time of second‐line TKI therapy initiation: eGFR ≥ 60, 30 ≤ eGFR < 60, and eGFR < 30. The eGFR slope during first‐line IO combination therapy was calculated using eGFR measurements when initiating first‐line and second‐line therapies. Multivariable Cox proportional hazards regression analyses were performed to evaluate the effects of renal impairment and eGFR slope on progression‐free survival (PFS) and overall survival (OS).

Results

The incidence rates of any grade and grade ≥ 3 adverse events were not significantly different among the three groups. Univariable analyses indicated that eGFR slope was not significantly associated with PFS or OS. Multivariable analyses suggested that moderate (30 ≤ eGFR < 60 mL/min/1.73 m 2 ) and severe (eGFR < 30 mL/min/1.73 m 2 ) renal impairment had no effects on shorter PFS, whereas severe renal impairment was independently and significantly associated with shorter OS.

Conclusions

TKIs can be safely used as a second‐line treatment after first‐line IO combination therapy in mRCC patients with renal impairment without sacrificing oncological outcomes, except for in patients with severe renal impairment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsProtein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsRenal InsufficiencyHumansRetrospective StudiesMaleFemaleMiddle AgedAgedGlomerular Filtration RateJapanProgression-Free SurvivalAdultTreatment OutcomeAged, 80 and overTyrosine Kinase InhibitorsEast Asian People

Stichwörter der Autor:innen

chronic kidney diseaseoncological outcomesrenal function declinesafetysecond‐line TKI

Substanzen

Protein Kinase InhibitorsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
  • Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Department of Urology, Aichi Cancer Center, Nagoya, Japan.
  • Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Urology, Hokkaido University Hospital, Sapporo, Japan.
  • Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.

ORCID-Profile: Naoki Fujita, Yuto Matsushita, Yukari Bando, Takahiro Osawa, Tomokazu Sazuka, Keisuke Goto, Shuya Kandori, Yoshihide Kawasaki, Takuma Kato, Makito Miyake, Kosuke Ueda, Hajime Tanaka, Shingo Hakakeyama

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Fujita, N., Matsushita, Y., Kojima, T., Bando, Y., Osawa, T., Sazuka, T., Goto, K., Numakura, K., Yamana, K., Kandori, S., Kawasaki, Y., Kato, T., Miyake, M., Fujita, K., Ueda, K., Tanaka, H., Tomida, R., Kitamura, H., Miyake, H., …, & Japanese Urological Oncology Group (2025). Impact of Impaired Renal Function on the Efficacy and Safety of Second‐Line Tyrosine Kinase Inhibitor Therapy After First‐Line Immuno‐Oncology Combination Therapy in Metastatic Renal Cell Carcinoma: A Japanese Multicenter Retrospective Study. International Journal of Urology. https://doi.org/10.1111/iju.70172

Vancouver

Fujita N, Matsushita Y, Kojima T, Bando Y, Osawa T, Sazuka T, et al. Impact of Impaired Renal Function on the Efficacy and Safety of Second‐Line Tyrosine Kinase Inhibitor Therapy After First‐Line Immuno‐Oncology Combination Therapy in Metastatic Renal Cell Carcinoma: A Japanese Multicenter Retrospective Study. International Journal of Urology. 2025. doi:10.1111/iju.70172

BibTeX
@article{Fujita2025,
  author = {Fujita, Naoki and Matsushita, Yuto and Kojima, Takahiro and Bando, Yukari and Osawa, Takahiro and Sazuka, Tomokazu and Goto, Keisuke and Numakura, Kazuyuki and Yamana, Kazutoshi and Kandori, Shuya and Kawasaki, Yoshihide and Kato, Takuma and Miyake, Makito and Fujita, Kazutoshi and Ueda, Kosuke and Tanaka, Hajime and Tomida, Ryotaro and Kitamura, Hiroshi and Miyake, Hideaki and Hakakeyama, Shingo and Japanese Urological Oncology Group, Japanese Urological Oncology Group},
  title = {Impact of Impaired Renal Function on the Efficacy and Safety of Second‐Line Tyrosine Kinase Inhibitor Therapy After First‐Line Immuno‐Oncology Combination Therapy in Metastatic Renal Cell Carcinoma: A Japanese Multicenter Retrospective Study},
  journal = {International Journal of Urology},
  year = {2025},
  doi = {10.1111/iju.70172}
}
Kostenlos starten →